Neurocrine Biosciences Inc. (NBIX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
48.46-0.71 (-1.44%)
At close: 4:00 PM EDT
People also watch:
ALKSLGNDPGNXNKTRINCY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open48.92
Prev Close49.17
Bid40.12 x 100
Ask58.00 x 100
Day's Range48.27 - 49.72
52wk Range31.25 - 58.46
1y Target EstN/A
Market Cap4.2B
P/E Ratio (ttm)-33.94
Beta0.04
Volume496,684
Avg Vol (3m)972,730
Dividend & Yield0.00 (0.00%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire10 hours ago

    Neurocrine Announces FDA Conditional Acceptance of Proprietary Name INGREZZA™ for VMAT2 Inhibitor Valbenazine

    SAN DIEGO, Aug. 31, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name "INGREZZA™" for the Company's once-daily vesicular monoamine transporter 2 (VMAT2) inhibitor valbenazine. The name INGREZZA (pronounced in-GREH-zah) was developed using the FDA's Guidance for Industry, Contents of a Complete Submission for the Evaluation of Proprietary Names consistent with the goal of preventing medication errors.

  • PR Newswire2 days ago

    Neurocrine Submits New Drug Application for Valbenazine for Treatment of Tardive Dyskinesia

    SAN DIEGO, Aug. 29, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for once-daily dosing of valbenazine in treating tardive dyskinesia. "This is an important milestone in the development of valbenazine for the treatment of tardive dyskinesia, a serious disease for which there is no FDA approved pharmaceutical treatment," said Kevin C. Gorman, President and Chief Executive Officer of Neurocrine Biosciences.

  • Capital Cube19 days ago

    ETF’s with exposure to Neurocrine Biosciences, Inc. : August 12, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Neurocrine Biosciences, Inc. Here are 5 ETF’s with the largest exposure to NBIX-US. Comparing the performance and risk of Neurocrine Biosciences, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)